Literature DB >> 20673618

Determination of cidofovir in human plasma after low dose drug administration using high-performance liquid chromatography-tandem mass spectrometry.

Jeremiah D Momper1, Shimin Zhang, Parmjeet S Randhawa, Ron Shapiro, Kristine S Schonder, Raman Venkataramanan.   

Abstract

A sensitive and specific method for the determination of cidofovir (CDV) in human plasma using high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) was developed and validated. Plasma samples were processed by a solid phase extraction (SPE) procedure using Varian SAX extraction cartridges prior to chromatography. The internal standard was (13)C5-Folic acid ((13)C5-FA). Chromatography was performed using a Luna C8(2) analytical column, 5 microm, 150 mm x 3.0 mm, using an isocratic elution with a mobile phase consisting of 43% methanol in water containing 12 mM ammonium acetate, at a flow rate of 0.3 mL/min. The retention times of CDV and (13)C5-FA were 2.1 min and 1.9 min, respectively, with a total run time of 5 min. The analytes were detected by a Micromass Quattro Micro triple quadrupole mass spectrometer in positive electron spray ionization (ESI) mode using multiple reaction monitoring (MRM). The extracted ions monitored following MRM transitions were m/z 280.0-->262.1 for CDV and m/z 447.0-->294.8 for (13)C5-FA (IS). The assay was linear over the range 20-1000 ng/mL. Accuracy (101.6-105.7%), intra-assay precision (4.1-5.4%), and inter-assay precision (5.6-6.8%) were within FDA limits. No significant variation in the concentration of CDV was observed with different sample storage conditions. This method is simple, adaptable to routine application, and allows easy and accurate measurement of CDV in human plasma. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673618      PMCID: PMC3654809          DOI: 10.1016/j.jpba.2010.06.034

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

Review 1.  Separation methods for antiviral phosphorus-containing drugs.

Authors:  B B Ba; M C Saux
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-11-25

2.  Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system.

Authors:  Noush Afarin Farasati; Ron Shapiro; Abhay Vats; Parmjeet Randhawa
Journal:  Transplantation       Date:  2005-01-15       Impact factor: 4.939

3.  High-performance liquid chromatographic determination of cytosine-containing compounds by precolumn fluorescence derivatization with phenacyl bromide: application to antiviral nucleosides and nucleotides.

Authors:  E J Eisenberg; K C Cundy
Journal:  J Chromatogr B Biomed Appl       Date:  1996-04-26

4.  Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients.

Authors:  Dirk R J Kuypers; Ann-Karolien Vandooren; Evelyne Lerut; Pieter Evenepoel; Kathleen Claes; Robert Snoeck; Lieve Naesens; Yves Vanrenterghem
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

Review 5.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

6.  Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection.

Authors:  L C Yuan; G J Samuels; G C Visor
Journal:  Am J Health Syst Pharm       Date:  1996-08-15       Impact factor: 2.637

7.  Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.

Authors:  C B de Oliveira; D Stevenson; L LaBree; P J McDonnell; M D Trousdale
Journal:  Antiviral Res       Date:  1996-07       Impact factor: 5.970

8.  Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.

Authors:  S R Brody; M H Humphreys; J G Gambertoglio; P Schoenfeld; K C Cundy; F T Aweeka
Journal:  Clin Pharmacol Ther       Date:  1999-01       Impact factor: 6.875

Review 9.  Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature.

Authors:  Frédéric Lamoth; Manuel Pascual; Véronique Erard; Jean-Pierre Venetz; Ghaleb Nseir; Pascal Meylan
Journal:  Antivir Ther       Date:  2008

10.  (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent.

Authors:  J J Bronson; L M Ferrara; M J Hitchcock; H T Ho; K L Woods; I Ghazzouli; E R Kern; K F Soike; J C Martin
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

View more
  3 in total

1.  Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection.

Authors:  J D Momper; Y Zhao; R Shapiro; K S Schonder; Y Gao; P S Randhawa; R Venkataramanan
Journal:  Transpl Infect Dis       Date:  2012-10-02       Impact factor: 2.228

2.  Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.

Authors:  Amy E Caruso Brown; Mindy N Cohen; Suhong Tong; Rebecca S Braverman; James F Rooney; Roger Giller; Myron J Levin
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

Review 3.  Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes, influenza and other viral infections.

Authors:  W M A Niessen
Journal:  Int J Mass Spectrom       Date:  2020-06-13       Impact factor: 1.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.